In yesterday’s Wall Street session, BioAtla Inc (NASDAQ:BCAB) shares traded at $1.88, up 11.90% from the previous session.
BCAB stock price is now 20.03% away from the 50-day moving average and -12.57% away from the 200-day moving average. The market capitalization of the company currently stands at $90.47M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $17, JMP Securities recently initiated with Mkt Outperform rating for BioAtla Inc (NASDAQ: BCAB). On May 05, 2022, Credit Suisse Downgraded its previous ‘Outperform’ rating to ‘Neutral’ on the stock reducing its target price from $35 to quote $5, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, MCBRINN SYLVIA, Director bought 4,000 shares of the company’s stock on Dec 26 ’23. The stock was bought for $9,320 at an average price of $2.33. Upon completion of the transaction, the Director now directly owns 15,125 shares in the company, valued at $28435.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 20 ’23, Chief Executive Officer SHORT JAY M PHD bought 50,000 shares of the business’s stock. A total of $106,910 was incurred on buying the stock at an average price of $2.14. This leaves the insider owning 1,439,283 shares of the company worth $2.71 million. A total of 19.39% of the company’s stock is owned by insiders.
During the past 12 months, BioAtla Inc has had a low of $1.14 and a high of $4.02. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 3.81, and a quick ratio of 3.81. The fifty day moving average price for BCAB is $1.5663 and a two-hundred day moving average price translates $2.150225 for the stock.
The latest earnings results from BioAtla Inc (NASDAQ: BCAB) was released for 2024-06-30.
